The Effect of Licopid and Bifid and Lactic Acid Bacteria Complex on Lysozyme Activity as the Factor of Nonspecific Immune Protection in Chronic Gastric and Duodenal Ulcer

The aim of the investigation is to study the effect of Licopid and bifid and lactic acid bacteria complex on Helicobacter pylori eradication and lysozyme activity as the factor of nonspecific immune protection in gastric and duodenal ulcer.

Materials and Methods. There were studied 30 patients suffering from Helicobacter associated gastric and duodenal ulcer, lysozyme activity was determined in 8 conditionally healthy individuals.

There were used endoscopic, cytomorphological, and immunological (polymerase chain reaction, photonephelometric) techniques. To study the effect of immunomodulator and probiotic on eradication and nonspecific immune protection, there were determined H. pylori contamination and lysozyme activity of oropharyngeal secretion and gastric juice before and after the treatment.

Results. The analysis of biopsy specimens and lysozyme biological tests revealed the use of immunomodulator (Licopid) and bifid and lactic acid bacteria complex combined with anti-Helicobacter pylori therapy increases H. pylori eradication and enhances lysozyme activity of saliva and gastric juice compared to data on quadroscheme.

Conclusion. The administration of Licopid and bifid and lactic acid bacteria complex can be recommended in complex therapy of patients suffering from Helicobacter associated gastric and duodenal ulcers.

1. Malshe P.C. Drinking air and maneuvering it to the pyloric region of the stomach for the treatment for Helicobacter pylori infection. Med Hypotheses 2010 Aug; 75(2): 155–161.
2. Mazepa V.N., Bokarev A.N., Shimshulin G.A. Polimeraznaya tsepnaya reaktsiya dlya vyyavleniya piloricheskogo khelikobaktera [Polymerase chain reaction for Helicobacter pylori detection]. 2000.
3. Pasechnikov V.D., Chukov S.Z. Klin Med — Clinical medicine 2000; 11: 9–12.
4. Standarty diagnostiki i lecheniya kislotozavisimykh i assotsiirovannykh s Helicobacter pylori zabolevaniy (chetvertoe Moskovskoe soglashenie). Metodicheskie rekomendatsii №37 Departamenta zdravookhraneniya goroda Moskvy [Standards of diagnosis and treatment of acid dependent and Helicobacter pylori associated diseases (the fourth Moscow agreement)]. Methodical recommendations No.37 of Moscow Health Department]. Moscow: TsNIIG; 2010; 12 p.
5. Zvyagintseva T.D., Ermolaev D.N. Rossiyskiy zhurnal gastroenterologii, gepatologii, koloproktologii — Russian Journal of Gastroenterology, Hepatology, Coloproctology 2002; 5(12): 26.
6. Malfertheiner P., Megraud F., O’Morain C. et al. Current concept in the management of Helicobacter pylori infection the Maastricht III Consensus Report. European Gastroenterol Rev 2005.
7. Shiotani A., Nishi R., Uedo N. Helicobacter pylori eradication prevents extension of intestinalization even in the high-risk group for gastric cancer. Digestion 2010 Jan 29; 81(4): 223–230.
8. Sun Q., Liang X., Zheng Q., et al. High efficacy of 14-day triple therapy-based, bismuth–containing quadruple therapy for initial helicobacter pylori eradication. Helicobacter 2010; 15: 233–238.
9. Aleksandrova V.A. Osnovy immunnoy sistemy zheludochno-kishechnogo trakta [Principles of the immune system of gastrointestinal tract]. Saint Petersburg: MAPO; 2006; 44 p.
10. Shcherbakov P.L., Tsukanov V.V., Amel’chugova O.S. Lecasij Vrac — Attending Doctor 2010; 2: 38–40.
11. Aruin L.I., Kapuller L.L., Isakov V.A. Morfologicheskaya diagnostika bolezney zheludka i kishechnika [Morphological diagnosis of gastric and intestinal diseases]. Moscow: Triada-Kh; 2009; 483 p.
12. Arutpyunyan V.M., Grigoryan E.G. Klin Meditsina — Clinical medicine 2003; 15: 33–35.
13. Kuz'min V.B., Dugina V.V. et al. Sposob lecheniya khelikobakter-assotsiirovannoy khronicheskoy duodenal’noy yazvy [Treatment techniques of Helicobacter associated chronic duodenal ulcer]. Patent RF №225277 ot 21 iyulya 2003 g. [Patent of Russian Federation No.225277 from 21st of July 2003].
14. Grinevich V.B., Zakharchenko M.M. Novye Sankt-Peterburgskie vrachebnye vedomosti — New Saint Petersburg Medical Bulletin 2003; 3: 13–20.
15. Illek Ya.Yu., Bezus E.V., Suslova E.V. Uspekhi sovremennogo estestvoznaniya — Modern Natural Science Advances 2009; 1: 15–18.
16. Isakova M.Yu. Rossiyskiy zhurnal gastroenterologii, gepatologii, koloproktologii — Russian Journal of Gastroenterology, Hepatology, Coloproctology 2002; 5(12): 2.
17. Kostyukevich O.I. Rus Med Z — Russian Medical Journal 2011; 5(19): 304.
18. Kornienko E.A., Drozdova S.N., Serebryannaya N.B. Ross Med Z — Russian Medical Journal 2008; 11: 168.
19. Khaitov R.M., Pinegin B.V. Immunologiya — Immunology 2003; 4: 196–203.
20. Tsimmerman Ya.S., Mikhaleva E.N. Klin Med — Clinical medicine 2003; 1: 40–44.
21. Chernin V.V., Bazlov S.N., Egorova E.N. Ross Gastroenterol Z — Russian gastroenterological Journal 1999; 4: 167.
22. Khachatryan Z.A., Ktsoyan Z.A., Manukyan G.P. et al. Predominant role of host genetics in controlling the composition of gut microbiota. European Gastroenterol 2008; 3: 3064.
23. Kuzmin V.B., Yakovlev M.G. et al. Sposob lecheniya yazvennoy bolezni dvenadtsatiperstnoy kishki [Treatment technique of duodenal ulcer]. Patent na izobretenie RF No.218445 ot 7 avgusta 2000 g. [Pa­tent for invention PF No.218445 dated 7^th of August 2000].

Dugina V.V., Shirali Rashmi, Lebedeva N.V., Babayan S.R., Rudakova G.V., Khrulyova N.S. The Effect of Licopid and Bifid and Lactic Acid Bacteria Complex on Lysozyme Activity as the Factor of Nonspecific Immune Protection in Chronic Gastric and Duodenal Ulcer. Sovremennye tehnologii v medicine 2012; (2): 91